# Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)

> **NCT05646199** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **University of Hull** · enrollment: 60 (estimated)

## Conditions studied

- Polycystic Ovary Syndrome

## Interventions

- **DRUG:** Metformin
- **DRUG:** Semaglutide Injectable Product

## Key facts

- **NCT ID:** NCT05646199
- **Lead sponsor:** University of Hull
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05646199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05646199, "Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05646199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*